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Abstract
Eosinophilic esophagitis (EoE) is an emerging esophageal inflammatory disorder affecting children and young adults. As a
relatively new disease, EoE is still burdened by frequent diagnostic and therapeutic pitfalls in clinical practice. This manu-
script posits a number of similarities with Crohn’s disease, which may help optimize EoE patient management.
Commonalities include epidemiologic trends (Westernized diseases, rising incidence, early-life risk factors), diagnostic
considerations (symptoms are poor predictors of disease activity, difficulties in disease activity assessment) and therapeutic
issues (similar natural history and therapeutic goals, induction and maintenance phases, combination of drug and endo-
scopic treatment, potential drug interchangeability, long-term unsolved issues). Physicians devoted to EoE should learn from
the extraordinary achievements fulfilled in Crohn’s disease: increased disease awareness, multidisciplinary specialized
clinics, structured childhood and transition programs, and an ongoing roadmap for personalized treatments, including
genetic susceptibility, risk factors for progression, genotype-phenotype correlation, drug monitoring and microbial data.
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Introduction
Eosinophilic esophagitis (EoE) is a chronic, immune/
antigen-mediated esophageal disease characterized
clinically by symptoms related to esophageal dysfunc-
tion and histologically by eosinophil (eos)-predominant
inflammation.1 In the early 1990s, two groups of inves-
tigators independently reported a series of young adult
patients, mostly male, with dysphagia, typical endo-
scopic findings and marked esophageal eosinophilia,
in the absence of clinical evidence of gastro-esophageal
reflux disease (GERD).2,3 Nevertheless, the disorder
was largely neglected during the 1990s and early years
of the 21st century, mostly because previous studies
from the 1970s and 1980s equated the presence of
esophageal eosinophils (eos) and GERD.4 A prime
example is a series of 19 patients with dysphagia/food
impaction, ringed narrowed esophagus and dense
eosinophilia requiring esophageal dilation, reported as
GERD patients in 2001.5 Like in GERD, the most
common esophageal disease, many pediatric and adult
EoE patients are still treated in clinical practice for
four to eight weeks, followed by repeat courses of
on-demand treatment intended to control symptoms.
Only since 2007 has EoE been recognized as a distinct
new condition with the publication of updated guide-
lines for diagnosis and management.6–8 Mounting
knowledge over the past decade has contributed to
situating EoE as a distinct chronic and progressive
inflammatory condition affecting pediatric and young
adult patients, with familial aggregation.9,10 Symptom
pattern usually consists of intermittent flare-ups,
with symptoms of esophageal dysfunction and acute
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episodes of food impaction, followed by remission
periods.8 Symptom severity and dietary restriction
negatively affect the quality of life of patients, especially
children and young adults.11,12 Furthermore, untreated
inflammation usually leads to long-term fibrostenotic
complications, like narrow-caliber esophagus and
esophageal strictures.13,14 Disease management is
increasingly complex, with different therapeutic assets
such as proton pump inhibitor (PPI) therapy, swal-
lowed topical steroids, dietary therapy, endoscopic dila-
tion and even biologic agents.15
This manuscript aims to discuss a relevant number of
potential similarities between EoE and Crohn’s disease
(CD), particularly emphasizing epidemiologic trends,
symptom pattern, impaired quality of life, natural history,
disease activity assessment and therapeutic approach.
Differences between EoE and CD
From an etiologic and pathophysiologic standpoint,
EoE and CD clearly are different diseases. EoE is an
antigen-mediated allergic disease, thought to be pre-
dominantly but not exclusively triggered by food anti-
gens.6–8 Elimination diets (mainly involving cow’s milk,
wheat and eggs) are effective in achieving clinical and
histological remission in a relevant proportion of
patients.16 In genetically predisposed individuals, envir-
onmental antigens stimulate an anomalous Th2 inflam-
matory response, which promotes trafficking of eos
limited to the esophageal mucosa. Activated eos secrete
proinflammatory and profibrotic mediators, cause local
tissue damage, and recruit additional inflammatory
cells (mast cells and fibroblasts), perpetuating the
inflammatory response and resulting in esophageal
remodeling.17 In contrast, the ultimate etiology of CD
remains unknown. One possibility is that environmen-
tal factors in genetically predisposed individuals trigger
a Th1/Th17 inflammatory response resulting in a dis-
turbed innate and adaptive immune response toward a
diminished diversity of commensal microbiota.18 An
interesting hypothesis in CD is that food-triggered
changes of the intestinal microbiome might cause a
proinflammatory state preceding the development of
inflammatory bowel disease (IBD). Indeed, an intact
intestinal epithelial barrier ensuring a normal bacterial
clearance of the intestinal surface is crucial to guarantee
intestinal homeostasis. Exclusive enteral nutrition is an
extensively studied, well-established, and valid
approach to the remission of pediatric CD.19
Interestingly, a fermentable carbohydrate restriction,
namely the low fermentable oligosaccharides, disacchar-
ides, monosaccharides and polyols (FODMAP) diet, has
been shown lately to be effective in controlling functional
gastrointestinal symptoms, but not the underlying
inflammation, in patients with IBD.20,21
Needless to say, functional status in EoE patients
is much better than that for patients with CD, in
which anemia, malnutrition, infections, surgical pro-
cedures and drug toxicity might be common. EoE
and CD are also different in terms of extension
through the gastrointestinal tract, gender predomin-
ance, extraintestinal manifestations, noninvasive
monitoring, therapy principles, and long-term compli-
cations. The main differences between EoE and CD
are exhibited in Table 1. A recent population-based
study has suggested an increased risk of multiple
autoimmune diseases in EoE patients, including CD
and ulcerative colitis,22 but these findings should be
further replicated.
Potential commonalities between EoE and CD
The main similarities shared by both disorders are
sketched in Table 2.
Genetic predisposition and risk of inheritance
A genetic predisposition to EoE and CD is supported
by evidence of familial clustering and twin studies.
Regarding EoE, family history has been reported in
2%–7% of patients9,10 and susceptibility has been
associated with genetic variants at 5q22 (TSLP) and
2p23 (CAPN14).17 Likewise, first-degree relatives of
patients with CD have a greater increased risk of
developing either CD and ulcerative colitis. Genetic
studies have identified so far 163 susceptibility loci
for IBD, mostly shared between CD and ulcerative
colitis.23
Epidemiologic trends
The first case series of EoE as a distinct new condition
were published in 1993 and 1994.2,3 Since then, EoE has
rapidly become a common global disease with a steadily
rising incidence in multiple, mostly industrialized, loca-
tions. A first systematic review with meta-analysis
exhibited a current pooled EoE incidence rate of 7.2/
100,000 people/year and prevalence rate of 26.3 cases/
100,000 people both in children and adults.24 However,
this could be an underestimate. In Switzerland (Canton
of Vaud), the prevalence rate in 2013 was 24.1/100,000
people,25 but the annual EoE incidence was 10.6 times
higher in the period from 2010 to 2013 when compared
to that in the period from 1993 to 2009. Recent adult
data in Spain (Castilla La Mancha) have shown preva-
lence rates of 44.6 cases/100,000 people.26 Finally,
prevalence rates in the United States have been
reported to be 56.7 cases/100,000 people, peaking in
men 35–39 years old with a rate of 114.6/100,000
people.27
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Overall, incidence rates for EoE are coming steadily
closer to that recently reported for CD in North
America,28 Europe,29 Spain30 and Switzerland31 (inci-
dence rates 9–20 cases per 100,000 people/year). Since
CD was first described in 1932,32 prevalence rates
(100–320 cases per 100,000 people) still remain higher
compared to those in EoE.30,31 These epidemiological
data are summarized in Table 3.
Large numbers of EoE cases have been reported in
North America, Western and Eastern Europe, and
Australia. Fewer cases have been reported in South
America, Asia and the Middle East; cases from
Northern Africa have recently been reported,33 and,
as of yet, none in Sub-Saharan Africa or India.34 In
contrast, CD has been reported worldwide, but the inci-
dence and prevalence appear to be lower in Asia and
the Middle East.28 Collectively, we do believe that epi-
demiological figures of EoE will soon catch up with
CD. EoE is becoming a global disease affecting children
and young adults who will suffer this chronic condition
for several decades, without reported complications or
mortality. Hence, similar and even higher prevalence
rates to that of CD are likely expected for EoE in the
next 10–20 years if current epidemiologic trends persist.
Environmental risk factors
It is intriguing to speculate about why the incidence of
EoE and, to a lesser extent CD, is increasing so rapidly
in Western countries, although these types of changes
usually indicate an environmental rather than a genetic
cause. The hygiene hypothesis has been largely sug-
gested as a potential cause of rising allergic and auto-
immune disorders in industrialized countries.35
Improved domestic hygiene and sanitation and smaller
families with less-crowded living conditions might
Table 1. Main differences between eosinophilic esophagitis and Crohn’s disease.
First description as a
distinct entity
1993 1932
Etiology Antigen-induced (mainly food) Uncertain
Pathophysiology Anomalous Th2 response Anomalous Th1/Th17 response
Extension Limited to the esophagus Entire GI tract
Functional status Better
(usually without anemia, malnutrition, sys-
temic manifestations, infectious complica-
tion, surgeries, or drug toxicity)
Worse
(anemia, malnutrition, systemic manifest-
ations, infectious complication, surgical
procedures, and drug toxicity may be
common)
Gender Male predominance (2–4:1) Slight female predominance
Noninvasive markers of activity None yet Imaging studies/stool markers
Extraintestinal manifestations To be defined Mainly musculoskeletal and dermatologic, less
common hepatobiliary, ocular, renal and
pulmonary.
Therapy principles Locally acting anti-inflammatory drugs
Esophageal dilation for fibrostenotic findings
Systemically active immunomodulatory drugs
( combination with topical therapies)
Surgery in case of complications
Efficacy of dietary therapy Empiric elimination diet (mainly involving milk,
wheat and eggs) can lead to disease
remission
Exclusive enteral nutrition can lead to disease
remission in pediatric patients
A low FODMAP diet may improve functional
gastrointestinal symptoms
Long-term clinical complications Esophageal strictures
As of yet no increased risk for esophageal
cancer demonstrated
Intestinal strictures and fistulizing disease
Increased risk for colorectal cancer and
small bowel cancer
Long-term drug-related
complications
Unknown yet for PPI and topical steroids Increased risk for lymphoproliferative disorders
with thiopurines
Increased melanoma and other skin cancer
risk for patients under TNF-antagonists
Increased risk for infectious diseases
Side effects of systemic steroids
GI: gastrointestinal; FODMAP: fermentable oligosaccharides, disaccharides, monosaccharides and polyols; PPI: proton pump inhibitors; TNF: tumor necrosis
factor.
764 United European Gastroenterology Journal 5(6)
account for a lower exposure to infectious agents
important for the development of immunoregulatory
mechanisms. In this regard, an inverse association
between H. pylori infection and EoE has been sug-
gested.36 Interestingly, several early-life exposures that
could theoretically affect the early-life microbiome have
been associated both with EoE and CD. Lack or non-
exclusive breastfeeding10,37–39 and early antibiotic
exposure40,41 have been consistently associated with
both diseases. As for EoE, cesarean delivery has also
Table 2. Potential similarities between eosinophilic esophagitis and Crohn’s disease.
Genetic basis and
inheritance risk
Susceptibility loci identified
Family history
Environmental risk factors Lack or non-exclusive use of breastfeeding
Early exposure to repeat antibiotic therapy
Westernized diet
Epidemiology Rising incidence, more common in Western/Northern countries
Affects predominantly pediatric and young adults
Natural history Chronic disease, typically with intermittent relapsing symptoms
Progression from inflammation to fibrostenotic remodeling
Quality of life Impaired with symptom severity and dietary restrictions
Improved with therapeutic interventions
Depth of inflammation Transmural
Phenotypes Inflammatory/fibrostenotic
Disease activity assessment Clinical manifestations poorly predict biological activity
Diagnosis Symptoms, endoscopic findings and histology
Therapeutic management Induction and maintenance of remission
Therapeutic goals Clinic, endoscopic and histologic remission (deep remission), but still lacking validated
definitions in both entities.
Resolution of fibrostenotic features
Therapeutic modalities Medical/dietary therapy
plus endoscopic dilation if required
Therapeutic agents targeting
selective interleukins in the
inflammatory cascade
Modest results, lack of response in all patients.
Unsolved issues Predictors of treatment response
Predictors of disease progression
Monotherapy vs. combination therapy
Do all patients need maintenance treatment?
Maintenance therapy discontinuation: who and when?
Challenges perceived by patients
and their relatives
Lack of disease awareness
Lack of childhood and transition experts
Lack of specialized multidisciplinary units
Limited access to quality endoscopy
Personalized treatments
Table 3. Incidence and prevalence rates of Crohn’s disease and eosinophilic esophagitis (EoE) in North America and Europe, including
Switzerland and Spain.
Incidence Prevalence
Crohn’s disease EoE Crohn’s disease EoE
North America27,28 Up to 20/100,000 year Up to 11/100,000 year 200/100,000 56.7/100,000
Europe29 14/100,000 year – 322/100,000 –
Castilla La Mancha, Spain26,30 8.9/100,000 year 6.37/100,000 year 137/100,000 44.6/100,000
Canton of Vaud, Switzerland25,31 Not determined 6.3/100,000 year 100.7/100,000 24.1/100,000
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been identified as an early-life risk factor.40 Therefore,
markers of early altered esophageal/intestinal micro-
biome may modulate the risk of EoE and CD later in
life. It is important to note that these interesting find-
ings have not been replicated in some studies.41,42 All of
these concepts have paved the way for the development
of fecal microbiota transplantation as an effective
therapy for a subset of patients with CD.43 Several dif-
ferences in the composition of the esophageal micro-
biome have been demonstrated in EoE as compared
to healthy controls, and its pathogenic role is currently
being evaluated.44
This incidence rise of both diseases in Western coun-
tries has been steadily followed in developing countries
paralleling the increase of Westernized diets, character-
ized by high protein and fat as well as excessive sugar
intake, with fewer vegetables and less fiber. The con-
sumption of caloric sweeteners in beverages, intake of
fast food (pizza, hamburgers, snacks, beverages)
and wheat-containing foods (pasta, bread, cakes) has
increased enormously over the past two decades and
continues to grow, since away-from-home-foods and
snacks account for almost 50% of daily consumed
food and energy.45 Noteworthy, this concept linking
Western lifestyle and CD led to the application of the
low FODMAP diet to CD.45 A recent meta-analysis
has shown that high dietary intakes of polyunsatur-
ated/omega-6 fatty acids and meat were associated
with an increased risk of CD, whereas high fiber and
fruit intakes were associated with decreased CD risk.46
Exclusive enteral nutrition and a low FODMAP diet
have recently been shown to be effective dietary inter-
ventions for CD.19–21 Since oligosaccharides contained
in fruits, cereals and vegetables exert a prebiotic effect
on the gastrointestinal microbiota, it seems conceivable
that the effects of microbiota and diet are directly inter-
related in CD.47,48 As for EoE, it remains unknown
what has actually changed in cow’s milk, wheat and
eggs, which have been staple foods in Western countries
for millennia. Changes in food sources, addition of
antibiotics/fertilizers, genetic modifications to plant
and animal foodstuffs, drastic accelerated processing
of food supplies and plastic or synthetic food packaging
have all been proposed as potential causes.34
Disease activity assessment
By definition, EoE is a clinicopathological disease. Both
clinical and pathologic information should be taken
into consideration and neither of these parameters
should be interpreted in isolation.1 The development
and validation of a symptom assessment instrument
for pediatric and adult EoE patients is a challenge for
a number of reasons. Children may not be able to fully
describe their symptoms and toddlers and small
children do not suffer from dysphagia and food impac-
tion, which nearly universally appears in adolescents
and adults. Furthermore, dysphagia may depend not
only on the existence of esophageal caliber abnormal-
ities or active mucosal inflammation, but also on the
consistency of the ingested food and behavioral adap-
tations, such as food avoidance, food modification, or
an altered eating pace. In spite of these considerations,
most physicians still feel symptoms are strong pre-
dictors of disease activity.49 In 2014, an international
group of experts developed and validated the EoE
activity index (EEsAI), a patient-reported outcome
(PRO) instrument to be used in adult patients that
quantifies not only the difficulties foreseen by patients
in eating eight different food consistencies, but also
dietary or behavioral modifications for the same food
consistencies.50 Two years later, this instrument was
evaluated in a multicenter multinational cohort of 269
adult EoE patients and compared to endoscopic and
histologic assessment.51 Esophageal symptoms alone
showed a quite modest predictive capacity for estimat-
ing the presence of either histological or endoscopic
remission in adult patients with EoE. Therefore, clin-
icians should not make assumptions about the bio-
logical activity of EoE based exclusively on
symptoms, and endoscopy and biopsy for diagnosis
and monitoring of the disease continue to be neces-
sary.52 Regarding CD, commonly used activity scores
are the Crohn’s Disease Activity Index (CDAI) and the
Harvey-Bradshaw Index. The CDAI was developed in
the 1970s to assess the degree of illness in individuals
with CD and has since been used widely in clinical trials
of the condition. The Harvey-Bradshaw Index is a sim-
plification of the CDAI, designed to make data collec-
tion and computation easier.53 Both have been
extensively criticized for heavy weighting on subjective
clinical symptoms, besides not being specific to discrim-
inate reliably functional symptoms related to specific
irritable bowel syndrome, which may be common in
patients with CD in remission.54 Conversely, it was
recently shown that half of the patients under
azathioprine and/or infliximab in clinical remission,
according to CDAI score, had endoscopic and/or
C-reactive protein evidence of residual active CD.55
The authors concluded that clinical symptoms scored
by CDAI are not a reliable measure of the underlying
biological activity of CD. As such, additional modalities
such as biomarkers, endoscopy, or imaging should be
implemented to understand the full image of biological
disease activity at baseline and during follow-up.56,57
Quality of life
IBD is a chronic debilitating illness with a significant
impact on the health status of children and young
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adults. Intestinal and extra-intestinal disease activity,
surgical interventions, drug-induced side effects and
related psychosocial factors all adversely affect several
patient outcomes including quality of life, psycho-
logical functioning and treatment adherence.58
Patients also show diminished ability to undertake
household and social activities; furthermore, recent stu-
dies suggest that 9% to 19% of patients with CD suffer
from short-term absences from work and 19% to 22%
are on long-term disability.59 Enormous efforts have
been made over the past decade to overcome the most
common challenges perceived by patients and their
relatives: lack of awareness of the disease, lack of multi-
disciplinary and specialized clinics, lack of experts on
childhood-onset IBD and transition from pediatric to
adult care, difficulties in bathroom access, limited
access to skilled psychologists, dietitians and IBD
experts, as well as open discussions of personalized
treatments.60,61
As for EoE, evolving evidence has lately highlighted
that symptom severity, biological disease activity and
dietary therapy negatively influence patient quality of
life, which is improved during the course of evaluation
and treatment.11,12,62 Therefore, reducing symptoms,
esophageal inflammation, optimizing dietary restric-
tions, and close monitoring of patients might be key
for improvement of quality of life.
Natural history
EoE and CD both are chronic and progressive diseases,
and in some patients persistent transmural inflamma-
tion with subsequent tissue remodeling results in fibros-
tenotic stricturing. In EoE, untreated symptoms and
inflammation can remain over years because of diag-
nostic delay,63 and there is a high likelihood of recur-
rence after discontinuing any modality of treatment.1
Two recent studies nicely showed that the prevalence of
esophageal strictures correlates with the duration of
untreated disease.13,14 Furthermore, subepithelial
fibrous remodeling significantly increases with age.64
As for CD, approximately 80% of patients have small
bowel involvement (30% distal ileitis, 50% ileocolitis),
20% have disease limited to the colon and 5% predom-
inant involvement of the upper gastrointestinal tract.
The typical course in patients with CD involving the
small and/or large intestine is one of intermittent
exacerbation of symptoms followed by periods of
remission. Almost 20% of patients progress to a more
aggressive phenotype at 90 days of diagnosis and 50%
will eventually develop a stricturing or fistulizing com-
plication 20 years after initial diagnosis, especially when
ileal and perianal disease were present at the time of
diagnosis.18 More specifically, strictures may occur in
one of three patients within 10 years of diagnosis.65
Therapeutic endpoints
The ideal treatment endpoints both for EoE and CD
would be complete resolution of symptoms, endoscopic
findings, and histologic inflammation in order to pre-
vent remodeling and related complications.18,66,67
Lately, mucosal healing (endoscopic remission) and
deep remission (clinical, biologic, endoscopic and histo-
logic remission) have been associated with improved
outcomes in CD, and consequently, are currently rec-
ommended as therapeutic targets.68 The lack of vali-
dated definitions, however, for symptom, endoscopic
and histologic remission both in EoE and CD consti-
tutes a major challenge. A panel of experts recently
defined clinical remission in CD as resolution of
abdominal pain and diarrhea/altered bowel habit,
whereas endoscopic remission was defined as resolution
of ulceration at ileocolonoscopy or finding of inflam-
mation on cross-sectional imaging.69 No consensus is
available on histologic remission yet.70 Regarding EoE,
the precise clinical (resolution of dysphagia?, what
score to use?, what about other symptoms?) and histo-
logic (no eosinophilic inflammation?,< 5 eos/high-
power field (HPF)?,< 15 eos/HPF?) targets for EoE
should also be a matter of debate.
Therapeutic management
The choice of therapy both for EoE and CD will vary
depending on the anatomic location of disease (only for
CD), the severity of the disease, phenotype, comorbid-
ities, individual characteristics of the drug and patient,
local expertise, costs and the ultimate goal of therapy
(i.e. induction or maintenance of remission).18,66,67
Both diseases have an induction phase, in which the
condition is brought under control, and a maintenance
phase, in which the main goals are preventing flares by
keeping patients in remission, thereby restoring their
quality of life. The therapeutic armamentarium for
both diseases includes dietary, pharmacologic and
endoscopic interventions. Drugs and dietary changes
target the inflammation associated with the disease
pathogenesis, whereas endoscopic dilation treats
fibrous remodeling and complications, but has no
effect on underlying inflammation.66,67
A further frustrating commonality between EoE and
CD is the lack of response in all patients when attempt-
ing to target specific interleukins (IL) within the inflam-
matory cascade with biologic therapies. Despite
potentially sound theoretical mechanisms of action
and initially promising data, many biologic drugs tar-
geting ILs have failed both in EoE (IL-5, IL-13)15 and
CD (IL-10).71 Possibly, the lack of a final common
inflammatory pathway likely inhibits yielding complete
response. Both conditions encompass a heterogeneous
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group of patients with variable disease courses. A road-
map for personalized disease treatment, based on gen-
etic susceptibility, genotype-phenotype concordance,
biomarkers, drug monitoring and microbial data, is
currently under development for CD,72,73 and so
should be in the foreseeable future for EoE.
Induction therapy. This treatment phase aims to achieve
symptoms and endoscopic remission (CD) and symp-
tom and histologic remission (EoE). In the majority of
EoE patients, a PPI should still be considered first, with
dietary therapy or swallowed topical corticosteroids
used if there is no PPI response.66,67 Patients with
severe fibrostenotic EoE or malnutrition at onset
might be better treated with potent anti-inflammatory
drugs (i.e. swallowed topical corticosteroids).1,66,67 A
follow-up endoscopy after an initial six- to eight-week
course of therapy should be carried out to document
histologic response.66 Regarding CD, a fast-acting
short-term agent (i.e. steroids or anti-tumor necrosis
factor (TNF)) is used to achieve rapid symptom
relief.18 Monitoring of treatment efficacy is usually
assessed by means of changes in symptom scores, non-
invasive biomarkers (serum reactive C protein and fecal
calprotectin), endoscopy and imaging techniques (e.g.
magnetic resonance enterography).57,74,75
Maintenance therapy. The choice of a long-term interven-
tion for maintenance therapy should aim to balance
efficacy with side effects and complications within a
given individual. For instance, dietary therapy in EoE
may not be a good choice in patients with a pre-existing
restrictive diet because of multiple food allergies or with
predictable poor compliance, but it can be evaluated in
patients unwilling to take long-term medications.
Likewise, methotrexate in CD might be a poor choice
for a patient of childbearing age or with pre-existing
liver disease, but can be an excellent option for a
patient with CD and arthropathy.
Maintenance therapy in EoE must be considered for
all patients, but particularly in those with severe dys-
phagia or food impaction, high-grade esophageal stric-
ture, and rapid symptomatic/histologic relapse
following initial therapy.1,66,67 However, there is con-
troversy about whether treatments should be continued
indefinitely, particularly in light of the potential side
effects and limited long-term data. In contrast to CD,
a trend toward tapering maintenance doses for PPI and
topical steroids is evident in EoE.76,77 Whether drug
doses for EoE may be used like in CD, not changing
what works for a patient from induction to mainten-
ance, should be clarified. It also remains unclear when
long-term endoscopic monitoring of disease activity
should be performed (every year, three or five years),
whether combination therapy may potentially and
synergistically enhance an anti-inflammatory
response,78 or if sustained histologic remission may
alter the natural history of the disease. Like in CD,
switching drug classes or from medications to diet
might also be feasible, as lately shown by two series
of patients with esophageal symptoms and eosinophilia
that responded not only to PPI therapy, but also to
diet/topical steroid therapy, and vice versa.79,80
Maintenance therapy and its unsolved issues in EoE
have correlates in CD. Medical therapies are intended
to modify the underlying disease process, in the hope of
achieving biologic remission and preventing harmful
complications. Mainly since 2013,81 endoscopic muco-
sal healing has been incorporated as a primary or sec-
ondary long-term endpoint in therapeutic algorithms.
A recent meta-analysis has shown that mucosal healing
predicts long-term clinical remission and fewer hospi-
talizations and surgeries.82 On the other hand, super-
iority of combination therapies with thiopurines and
TNF blockers for improved symptom control and
mucosal healing should be balanced with the increased
risk of infectious and malignant complications.
A recent systematic review showed that more than
50% of patients with IBD who discontinued an immu-
nomodulator after combination therapy had a disease
relapse.83 Therefore, accurate identification of sub-
groups of patients who are good candidates for discon-
tinuation of treatment is required. Switching drug
classes or agents is common in CD for a number of
reasons like primary non-response, loss of response,
insufficient efficacy (i.e. absence of mucosal healing),
and intolerance or unacceptable side effects.18 The opti-
mal duration of maintenance therapy is unclear yet,
and studies are needed to identify subgroups of patients
in whom treatment can be discontinued.
Treatment of stricturing disease. Endoscopic dilation can
offer symptomatic response in case of stricturing EoE
and CD. However, repeated dilations are often needed,
and long-term outcomes of endoscopic balloon dilation
remain to be investigated.84,85 Topical steroids and diet-
ary therapy in EoE have shown their ability to reverse
subepithelial fibrosis.64,86,87 Whether medical/dietary
therapy can be effective coadjuvant treatments for dila-
tion or after dilation in EoE is yet to be determined.
Likewise, the role of medical therapy in stricturing CD
is controversial. Differentiating inflammatory from
fibrotic strictures remains challenging. Medical therapy
with biologics may play a role in CD stricture with an
inflammatory component and/or concurrent inflamma-
tion adjacent to the stricture area. Although biological
therapy may reduce the risk for the formation of stric-
tures from mucosal inflammation, rapid mucosal heal-
ing from potent biological agents may predispose
patients to the development of new strictures or
768 United European Gastroenterology Journal 5(6)
worsening of existing strictures.85 Additionally, there is
no clear evidence about the efficacy of postdilation
medical therapy to prevent recurrence of strictures.85
Conclusions and research agenda
Through a relevant number of comparisons between
EoE and CD, this review paper underscores salient fea-
tures, and unmet diagnostic and therapeutic needs, that
may be common for both disorders. Like in CD, the
upcoming research agenda for EoE should be oriented
to fill diagnostic gaps, mainly measuring disease activity
and deep remission, and pursue personalized treat-
ments reversing the progressive natural history of the
disease, by means of increasing our knowledge of risk
factors for progression, adequate identification of
phenotypes, genotype-phenotype concordance, drug
doses and monitoring, and esophageal microbiome
data. All these data will allow us to better predict out-
comes for individual patients and to precisely tailor
therapy.
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